Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition
Portfolio Pulse from Vandana Singh
Novo Nordisk has discontinued its long-acting insulin Levemir in the U.S. due to manufacturing constraints, reduced patient access, and the availability of alternative options. This will lead to supply disruptions starting in mid-January, with the discontinuation of the Levemir injection pen in April next year and Levemir vials by the end of 2024. Novo Nordisk's other long-acting insulin, Tresiba, remains on the market. NVO shares are down 0.99% at $100.75 during the premarket session on the last check Thursday.
November 09, 2023 | 2:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's decision to discontinue Levemir in the U.S. could impact its market share and revenues. However, the company's other long-acting insulin, Tresiba, remains on the market. NVO shares are down 0.99% in premarket trading.
The discontinuation of Levemir in the U.S. could lead to a decrease in Novo Nordisk's market share and revenues, as it is one of the company's products. This could negatively impact the company's stock price in the short term, as reflected in the 0.99% decrease in premarket trading. However, the company's other long-acting insulin, Tresiba, remains on the market, which could mitigate some of the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100